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Abstract: The vast majority of patients with inflammatory bowel 
disease (IBD) will receive immunosuppressive therapy at some 
point for their disease, whether for the short term (such as a course 
of corticosteroids) or long term (such as maintenance therapy with 
immunomodulators or biologics). The systemic immunosuppres-
sion places patients at increased risk for infections. Therefore, it 
is important that patients are up-to-date with immunizations to 
minimize vaccine-preventable infections. However, the literature 
shows that the rate of immunization in patients with IBD is low. 
Ideally, the vaccination status is checked at diagnosis, and patients 
are immunized with the vaccines they need. Drawing titers is help-
ful in cases in which vaccination history is unclear or to confirm 
that titers are at an adequate level in cases in which patients have 
been vaccinated. Current guidelines recommend that patients with 
IBD follow the same routine immunization schedule as healthy 
children, but patients should not be administered live vaccines 
if they are receiving immunosuppressive therapy. Therefore, it is 
ideal to administer any necessary vaccinations as early as possible, 
prior to starting immunosuppressive therapy. Patients may receive 
inactivated vaccines regardless of immunosuppressive status. The 
IBD literature suggests that inactivated vaccines are safe and do 
not worsen disease activity. In general, patients with IBD mount 
an immune response to vaccines, but the response may be lower 
if patients are receiving immunosuppressive therapy, especially 
tumor necrosis factor inhibitors.
Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract. The specific patho-genesis of IBD remains unknown, but growing evidence in the 
literature has identified over 140 genetic variants (such as NOD2 
and interleukin-23R).1-4 The genetic alterations, in combination 
with environmental factors, ultimately lead to altered mucosal 
immunity, which in turn can lead to intestinal inflammation or 
fibrosis.5 In addition to having a suboptimal innate immunity, the 
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immune system of patients with IBD may be further 
weakened by medications used to treat their disease. 
The vast majority of children and adults who have 
Crohn’s disease and ulcerative colitis will likely be treated 
with immunosuppressive medications at some point in 
the course of their disease, either in the short term to 
induce remission (such as with a course of corticoste-
roids) or in long-term maintenance therapy (such as 
with immunomodulators or tumor necrosis factor 
[TNF]-alpha inhibitors).6
Immunosuppressive medications are a double-edged 
sword. Although these potent medications may help con-
trol disease activity, they also put patients at an increased 
risk for opportunistic infections and associated complica-
tions,7 such as cytomegalovirus,8,9 Epstein-Barr virus,10 
hepatitis B virus (HBV) reactivation in latent infec-
tion,11-14 varicella,15-17 and histoplasmosis.18,19 Similarly, a 
few studies have found that there is a higher prevalence 
of cervical dysplasia in women with IBD compared with 
healthy age-matched controls,7,20,21 and immunosuppres-
sive therapy is a risk factor for having an abnormal Pap 
smear.7,21,22 Another study revealed that patients with IBD 
are at an increased risk for bacterial pneumonia compared 
with the general population. When patients with IBD 
with pneumonia were compared with patients with 
IBD without pneumonia, immunosuppressive therapies 
(including corticosteroids, thiopurines, and biologics) 
were found to be risk factors for pneumonia.23 
Immunizations Are Underutilized 
Fortunately, there are methods to minimize infections. 
They include proper hand washing or use of alcohol-based 
hand sanitizers, avoidance of sick contacts, administration 
of prophylaxis if exposed, adequate nutrition, and main-
tenance of a healthy lifestyle. Another way to minimize 
infections (eg, influenza, human papillomavirus [HPV], 
and varicella) is through vaccination. However, the valu-
able tool of vaccination is underutilized by both the gas-
troenterologist and patient. 
A survey by Wasan and colleagues of gastroenterolo-
gists who treat adult patients revealed that the majority 
believed the responsibility to ensure that patients with IBD 
were up-to-date with immunizations should fall on the 
primary care physician (PCP).24 However, some patients 
with IBD visit the gastroenterologist more frequently 
than the PCP and may view the gastroenterologist as their 
primary medical care provider. Therefore, gastroenterolo-
gists should be mindful of patients’ immunizations. 
It is important for gastroenterologists to educate 
both patients and PCPs about immunizations by includ-
ing a reminder in the consult note and to ensure that 
patients are receiving the appropriate vaccines at the 
appropriate time (either at their own office or the PCP’s). 
However, the survey by Wasan and colleagues found that 
only approximately half of gastroenterologists routinely 
inquired about patients’ vaccination history, and being 
“too busy/forgot” was the most common reason for not 
regularly recommending an immunization.24 In addition, 
only 12% of gastroenterologists could correctly answer 
which vaccines should or should not be administered 
when patients are receiving or not receiving immunosup-
pressive medications. Patients disclosed that the clinician 
who encouraged them to receive the influenza vaccine 
was primarily their family physician, followed by family/
friends and then their gastroenterologist.25
Patients with IBD have a low rate of immunization 
for vaccine-preventable diseases. Melmed and colleagues 
surveyed 169 adults with IBD about their immunization 
history and exposure risk.26 The study found that only 
28% routinely received influenza vaccine, 9% received 
pneumococcal vaccination, and 45% had a tetanus 
booster within the past 10 years. However, the rate of 
routine immunizations in children in certain parts of Aus-
tralia and Canada is approximately 90%.27,28 Interestingly, 
a study by Crawford and colleagues found that adherence 
to additional recommended vaccines was poor, with only 
5% of children receiving a pneumococcal booster and 
only 10% receiving influenza vaccine.27 
Common reasons patients have for not receiving 
influenza vaccination include fear of adverse effects or seri-
ous complications, belief that the vaccine is not effective, 
concern that the vaccine will induce an IBD flare, lack 
of awareness that the vaccine is indicated, belief that the 
vaccine is unnecessary, and, importantly, the medical care 
provider either did not offer the vaccine or advised against 
it.25-27 A number of recent reviews and guidelines provide 
important information on appropriate use of vaccines.
Immunization Guidelines 
There are many different published recommendations 
on vaccinating immunocompromised patients. Such 
“guidelines” are often limited by a lack of primary data 
and discrepant recommendations between authorities. In 
2013, the Infectious Disease Society of America (IDSA) 
prepared a comprehensive document of recommenda-
tions outlining the controversies.29 This IDSA Guideline 
is freely available online at http://www.idsociety.org/Tem-
plates/Content.aspx?id=32212256011 and can be used 
by practitioners in cases of clinical uncertainty.
Current immunization guidelines recommend vac-
cinating all patients with IBD with inactivated vaccines, 
regardless of immunosuppression status. Therefore, 
patients with IBD generally follow the same routine vac-
cination schedule as the general population. However, live 
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vaccines—such as measles, mumps, and rubella (MMR), 
varicella, and intranasal influenza vaccines—should not 
be given to immunosuppressed patients. A number of 
studies on the safety and immunogenicity of inactivated 
vaccines in patients with IBD have been conducted; how-
ever, there remains a paucity of data on live vaccines.
When Are Patients Considered to Be 
Immunosuppressed?
Patients with IBD on aminosalicylate monotherapy are 
not considered immunosuppressed and should follow 
the same routine vaccination schedule as the general 
population. Patients considered to be immunosuppressed 
are those receiving 6-mercaptopurine (6-MP), azathio-
prine, methotrexate, biologics, tacrolimus, cyclosporine, 
or high-dose corticosteroids (defined as ≥20 mg/day, or 
≥2 mg/kg/day if <10 kg, of prednisone or its equivalent if 
used for at least 14 days). 
It is recommended that immunosuppressive therapy 
be discontinued for at least 3 months prior to administer-
ing live vaccines, with the exception of corticosteroids, 
which should be discontinued for at least 1 month. If live 
vaccines are to be administered prior to starting immuno-
suppressive medications, then it is optimal to wait at least 
4 weeks after varicella vaccination and at least 6 weeks 
after MMR vaccination before initiating immunosup-
pressive therapy. Patients who are severely malnourished 
are also considered immunosuppressed.30-32
When to Immunize
The ideal time to check a patient’s immunization status 
and administer “catch-up” vaccines is at the diagnosis of 
IBD. This is especially important for live vaccines, which 
should be administered prior to initiating immunosuppres-
sive therapy. Fortunately, because live vaccines (eg, MMR 
and varicella) are routinely recommended and adminis-
tered to young children, most children with IBD would 
have already received live vaccines by the time of diagnosis 
because it is less common for children to present at younger 
than age 5 years. However, in cases in which patients are 
“behind” on vaccines and will be placed on aminosalicylates 
as maintenance therapy but need to start corticosteroids for 
induction of IBD, it may be better to wait until after cor-
ticosteroids are weaned before administering live vaccines. 
In cases in which patients will be started on immu-
nosuppressive agents as maintenance therapy (with or 
without corticosteroids), it is important to obtain immu-
nization records to ascertain which vaccines have not been 
administered and discuss the risks and benefits of immu-
nizing (and withholding therapy) vs starting immunosup-
pressive therapy first with patients and their families.
In general, checking serology is helpful in cases 
in which the immunization status is unclear. Even in 
patients who have a history of vaccination, obtaining 
titers is useful in assessing whether antibodies are at an 
adequate level because titers may diminish over time.26,33 
Titers commonly available in laboratories include those 
for hepatitis A virus, HBV, MMR, and varicella.
Assessing Vaccine Efficacy 
Vaccines contain live attenuated or killed inactivated 
microorganisms or synthesized particles that act as antigens 
to trigger a cascade of immune reactions in the body, ulti-
mately leading to formation of antibodies and memory cells 
that will be activated should there be an exposure to the 
wild-type organism in the future. Typically, investigators 
obtain a blood sample before and at a certain time interval 
after administration of a vaccine to measure antibody titer 
levels. The extent of immune response is made by compar-
ing the antibody titer levels at the 2 time points. 
Various terms may be used to describe vaccine 
immunogenicity. Seroconversion is the development of 
antibodies after vaccination in a person who did not pre-
viously have a detectable titer. A person is considered sero-
protected if the antibody level has reached or exceeded the 
minimum threshold considered necessary to be protective 
against wild-type infection. Geometric mean titer (GMT) 
is defined as the average titer in a group of patients who 
have been vaccinated.
Routine Vaccines
The following section is a summary of the 2013 routine 
vaccine recommendations for children and adolescents by 
the Centers for Disease Control and Prevention and Advi-
sory Committee on Immunization Practices34 (Table). 
Data available on the immunogenicity and safety of each 
vaccine in patients with IBD are also reviewed.
Inactivated (Killed) Vaccines
Hepatitis A Virus  The hepatitis A virus vaccine is a 
2-dose regimen administered 6 to 18 months apart. The 
first dose is generally given at age 12 to 23 months. Two 
pediatric studies suggest that children with IBD have 
excellent immunogenicity (seroconversion rates of 97% 
to 100%) and are similar to healthy controls (100%) 
after completing the 2-dose series.35,36 However, 1 of 
these studies found that the seroconversion rate was lower 
after the first vaccine dose in patients with IBD (39%) 
compared with controls (64%; P=.00001). This empha-
sizes the importance of completing the vaccine series as 
recommended.35 The vaccine was well tolerated without 
worsening of disease activity.35,36
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A high seroconversion rate of 97.6% was also found 
in a study of 419 adult patients with IBD after complet-
ing the 2-dose series. However, the seroconversion rate 
was lower in patients receiving TNF inhibitor therapy 
compared with patients who were not on such therapy 
(92.4% vs 99.1%; P=.001) as well as in patients treated 
with 2 or more immunosuppressive agents compared 
with patients on fewer than 2 immunosuppressive agents 
(92.6% vs 98.4%; P=.03). Response rates were similar 
between patients on TNF inhibitor monotherapy and 
patients on a TNF inhibitor combined with another 
immunosuppressant.37
Hepatitis B Virus  The HBV vaccine is a 3-dose series 
typically given in infancy and early toddlerhood. It 
is important to check that patients are negative for 
HBV infection, especially prior to starting immuno-
suppressive therapy, including biologics, as cases of 
viral reactivation have occurred in patients with latent 
HBV infection treated with TNF inhibitors, result-
ing in severe viral hepatitis and/or liver failure.11-14 If 
patients are seronegative for HBV, they should be given 
the vaccine series (at Months 0, 1, and 4-6) and have 
titers rechecked 1 month after completing the series. 
If patients do not mount an adequate response, they 
should be revaccinated using a double dose following 
the standard HBV vaccine regimen or an accelerated 
schedule (Months 0, 1, and 2).31,34,38
A study by Gisbert and colleagues38 in 148 adult 
patients with IBD suggests that seroconversion (defined as 
anti-HBV surface antigen [HBs] >10 IU/L) is higher for 
those who followed the accelerated double-dose schedule 
compared with the standard dose (75% vs 41%; P<.001). 
In another study by Gisbert and colleagues39 involv-
ing 241 adult patients with IBD who were immunized 
with the double-dose accelerated HBV vaccine schedule, 
seroconversion occurred in 59%, and complete response 
(anti-HBs >100 IU/L) occurred in 39%. Older age and 
use of anti-TNF therapy were associated with poorer 
immunogenicity. Treatment with thiopurines or metho-
trexate did not influence immune response. Patients with 
anti-HBs less than 100 IU/L were revaccinated using the 
same double-dose accelerated schedule. Of the 95 patients 
who received the second set of vaccinations, 42% had a 
complete response.
In one pediatric study, children who had not been 
immunized against HBV were given the vaccine series. 
Seroconversion (anti-HBs ≥10 mIU/mL) occurred in 
70% of patients with IBD and 90% of healthy controls 
(P=.02). A booster dose was administered to children 
who did not seroconvert. Response then occurred in 
50% (7/14) of patients with IBD and 60% (3/5; P=NS) 
of controls.36 In the adult IBD literature, an adequate 
immune response to HBV vaccination occurred in 48% 
to 76% of patients.40,41 There were no vaccine-associated 
serious adverse events.36,38,40
In a prospective study of 100 children and young 
adults treated with infliximab (Remicade, Janssen) for 
IBD, patients were asked about their history of HBV 
vaccination, and serology for HBV was drawn.42 Thirteen 
percent of the patients had never been immunized against 
HBV. Of the 87 children who had been immunized 
(mean time of 13 years prior to drawing titers), 49 (56%) 
had immunity (defined as anti-HBs ≥10 mIU/mL). Older 
age, lower albumin levels, and presence of pancolitis were 
associated with lack of a protective antibody level. Con-
current use of immunomodulators with infliximab was 
not associated with lack of immunity. 
A booster dose was administered to patients who 
had received the vaccine series prior to the study but were 
found to lack immunity. Of the 34 patients who received 
a booster vaccine, 26 (76%) mounted an anamnestic 
response. Children who did not mount a response to the 
booster dose tended to receive infliximab more frequently 
compared with those who responded (every 5.9 ± 1.2 
weeks vs every 7.1 ± 1.8 weeks; P=.01).
Another study by Gisbert and colleagues of 100 adult 
patients with IBD found that the cumulative loss of anti-
HBs titers (<10 IU/L) was 2% at 6 months and 15% at 
12 months postvaccination.43 TNF inhibitor therapy was 
associated with a 3-fold increased risk of loss of response. 
Other studies found that suboptimal immunogenicity 
was associated with IBD duration of 110 months or more, 
albumin levels greater than 3.6 mg/mL, active IBD, and 
immunosuppressive therapy.38,40,41
Table. Routine Immunizations for Children 
Age Range
Inactivated  
Vaccines
Live  
Vaccines
Infancy and  
toddlerhood
(birth to 3 years old)
Hepatitis A virus
Hepatitis B virus
DTaP1 
Hib2
Pneumococcal (PCV13)
IPV3 
Rotavirus
MMR6
Varicella
Early childhood
(4-6 years old)
DTaP1
IPV3
MMR
Varicella
School-age and 
adolescence
(7-18 years old)
Tdap4
HPV5
Meningococcal
Annually Influenza  
(intramuscular)
Influenza 
(intranasal)
DTaP, diphtheria and tetanus toxoids and acellular pertussis; Hib, Haemophilus 
influenzae type b; HPV, human papillomavirus; IPV, inactivated poliovirus; 
MMR, measles, mumps, and rubella; PCV13, pneumococcal conjugate vaccine; 
Tdap, tetanus and diphtheria toxoids and acellular pertussis.
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Diphtheria, Tetanus, and Pertussis  The diphtheria and 
tetanus toxoids and acellular pertussis vaccine is a 5-dose 
series typically administered at ages 2, 4, 6, and 15 to 18 
months and 4 to 6 years. The tetanus and diphtheria tox-
oids and acellular pertussis vaccine is recommended at age 
11 to 12 years followed by a tetanus and diphtheria booster 
every 10 years. Data on the tetanus booster currently exist 
only in adult patients, and findings are conflicting. Some 
studies demonstrate a defective formation of B cells after 
vaccination,44,45 whereas other studies suggest an appropri-
ate immune response in patients with IBD.46,47
Haemophilus Influenzae Type B  The Haemophilus influ-
enzae type b (Hib) conjugate vaccine is administered as a 
primary 3-dose series in infancy (at ages 2, 4, and 6 months) 
and a booster at age 12 to 15 months. Data on the Hib vac-
cine and IBD are limited to one adult study consisting of 31 
patients with Crohn’s disease and 12 patients with ulcerative 
colitis who were immunized 24 weeks after starting 6-MP.46 
Thiopurine use did not suppress cellular or humoral immune 
response. In addition, patients tolerated the vaccine without 
worsened disease severity of IBD. 
Pneumococcal  The pneumococcal conjugate vaccine is 
given as a primary series in infancy (at ages 2, 4, and 6 
months) and a booster at age 12 to 15 months. To date, 
there are no studies on this specific vaccine in children 
with IBD. However, the adult IBD literature is consistent 
in finding that immunogenicity to the 23-valent pneumo-
coccal polysaccharide vaccine is poorer in patients receiv-
ing TNF inhibitor therapy (either as monotherapy or in 
combination with immunomodulators, 45% to 63%) 
compared with patients not receiving immunosuppressive 
therapy (78% to 89%) and healthy controls (85%).48-50 
Immunomodulator monotherapy was not associated with 
a hindered immune response (79%). The vaccine was well 
tolerated without serious adverse events.49,50
Poliovirus  The inactivated poliovirus (IPV) vaccine has 
replaced the live attenuated oral poliovirus vaccine in 
the United States due to concern for vaccine-associated 
paralytic poliomyelitis. IPV is routinely given as a primary 
series at ages 2, 4, and 6 to 18 months and as a booster at 
age 4 to 6 years. There are currently no studies on poliovi-
rus vaccine in patients with IBD. 
Human Papillomavirus  HPV vaccine is available as either 
a bivalent (HPV2; Cervarix, GlaxoSmithKline) or quadri-
valent (HPV4; Gardasil, Merck & Co) vaccine. Both HPV2 
and HPV4 immunize against HPV types 16 and 18, which 
are responsible for approximately 75% of cervical cancers. 
The advantage of HPV4 is that it also immunizes against 
HPV types 6 and 11, which cause approximately 90% of 
genital warts. Both vaccines are licensed for girls age 9 to 26 
years. However, only the HPV4 vaccine is licensed for boys 
(also for ages 9 to 26 years), who often tend to be asymp-
tomatic carriers and distributors of the virus. The HPV 
vaccine is generally recommended at age 11 to 12 years and 
is given as a 3-dose series at Months 0, 1 to 2, and 6. 
Jacobson and colleagues administered 3 doses of the 
HPV4 vaccine to 37 girls and young women age 9 to 
26 years receiving immunomodulator or TNF inhibitor 
therapy for IBD (prospective group).51 Antibody levels to 
each serotype were obtained immediately prior to the first 
dose and 1 month after the final dose. The investigators 
also drew titers in 15 girls and young women with IBD 
on immunomodulator or TNF inhibitor therapy who had 
previously completed the 3-dose HPV vaccine series at 
their pediatrician’s office (range, 0.5 to 27 months prior to 
enrollment, retrospective group). All patients in the pro-
spective and retrospective groups mounted an excellent 
immune response, with 100% seropositivity to HPV types 
6, 11, and 16. Seropositivity was lower for type 18 (96% 
in the prospective group and 40% in the retrospective 
group). GMTs for each serotype in the prospective group 
were similar to those of healthy historical female controls 
from Merck studies. There were no serious adverse events 
or worsened disease activity related to the vaccine.
Meningococcal  The quadrivalent meningococcal con-
jugate vaccine is generally recommended at age 11 to 12 
years, with a booster at 16 years. If the first dose is given at 
age 13 to 15 years, then a booster is recommended at age 
16 to 18 years, with a minimum of 8 weeks between doses. 
A booster is not indicated if the first dose is given after age 
16 years. Dorming college freshmen and graduating high 
school seniors who expect to dorm should be given 1 dose if 
they have not been immunized. No data currently exist on 
the meningococcal vaccine in patients with IBD.
Influenza  The influenza vaccine is available as an inac-
tivated form, administered intramuscularly for children 
age 6 months and older, and as a live attenuated form, 
administered intranasally for children age 2 years and 
older. Children age 8 years and younger who have not 
been previously immunized with influenza should receive 
2 doses at least 4 weeks apart. It is recommended that 
patients with IBD receive the intramuscular form of the 
influenza vaccine and, when available, the influenza/
swine combination vaccine each year. For patients with 
known or suspected influenza infection, physicians 
should consider withholding immunosuppressive therapy 
until the patient clinically improves and his or her infec-
tion resolves. Antiviral medications, such as oseltamivir, 
should be given if clinically indicated, regardless of the 
patient’s immunosuppression status.
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The pediatric IBD data demonstrate that the inacti-
vated trivalent influenza vaccine is safe and without seri-
ous adverse events.52,53 In addition, the vaccine does not 
appear to worsen IBD activity. Disease activity scores pre- 
and postvaccination (as measured by the Pediatric Crohn’s 
Disease Activity Index for Crohn’s disease and the Modi-
fied Harvey-Bradshaw score or Lichtiger Colitis Activity 
Index for ulcerative colitis or indeterminate colitis) were 
not statistically significant.52,53 The vaccine is generally 
immunogenic, especially to the two A strains. However, 
patients on immunosuppressive therapy, especially TNF 
inhibitors, have a poorer response to strain B compared 
with patients not receiving immunosuppressive therapy 
and healthy controls.52-54
Vaccine studies in adult patients with IBD that 
evaluated the 2009 H1N1 influenza vaccine agree that the 
vaccine is generally well tolerated.55,56 Immunogenicity is 
lower in patients on TNF inhibitor therapy compared 
with patients on nonimmunosuppressive therapy and 
healthy controls. Moreover, immune response is poorer 
for patients on combination therapy (TNF inhibitor 
combined with a thiopurine or corticosteroids) compared 
with patients on TNF inhibitor monotherapy.
Live Attenuated Vaccines
Measles, Mumps, and Rubella  The first dose of the 
MMR vaccine is typically administered at age 12 to 15 
months. The second dose is administered at age 4 to 6 
years; however, the second dose may be given earlier than 
age 4 years as long as there is a minimum of 4 weeks 
between the 2 doses. 
If the vaccination history is unclear, titers to indi-
vidual components of the vaccine should be obtained, 
and patients should be vaccinated if they lack immunity. 
However, because the MMR vaccine is a live vaccine, it 
is currently not recommended in patients with IBD who 
are receiving immunosuppressive therapy.30 If there is 
anticipation to start immunosuppressive medications, it 
is advised to wait at least 6 weeks after vaccination.31
The data currently available on adult patients with 
IBD suggest that approximately 30% to 37% are sero-
negative to measles, mumps, and/or rubella, even if they 
had a history of wild-type infection.57,58 Fifty-four percent 
of patients receiving immunosuppressive therapy were 
found to be seronegative to 1 or more viral components 
of the MMR vaccine.58 To date, there are no data on 
the immunogenicity of the MMR vaccine in pediatric 
patients with IBD.
Varicella  The varicella vaccine is a 2-dose regimen. The 
first dose is typically administered at age 12 to 15 months 
and the second dose at age 4 to 6 years. The second dose 
can be given before age 4 years; however, it is preferred that 
there is a minimum of 3 months between doses (although a 
minimum of 4 weeks is also acceptable). For children age 7 
to 12 years who need to “catch up,” the 2 doses should be at 
least 3 months apart (although a minimum of 4 weeks is also 
acceptable). For children age 13 years and older who need to 
be immunized, the 2 doses should be at least 4 weeks apart.
Guidelines currently recommend that the varicella 
vaccine, which is live, not be given to patients with IBD 
who are receiving immunosuppressive therapy.30 It is 
even more important, however, to protect this vulnerable 
subpopulation against wild-type infection because these 
patients are at an increased risk for complications of vari-
cella virus infection, some of which can be severe.15-17 
Interestingly, although the zoster vaccine has at least 
10 times more varicella zoster virus than the varicella 
(chickenpox) vaccine, the zoster vaccine is recommended 
for adult patients on low-dose corticosteroids (<20 
mg/day prednisone or equivalent), a short course of cor-
ticosteroids (<14 days), 6-MP at up to 1.5 mg/kg/day, 
azathioprine at up to 3 mg/kg/day, or methotrexate at up 
to 0.4 mg/kg/week.31,59 
If patients are not on immunosuppressive medica-
tions, they should be vaccinated if there is no history of 
chickenpox infection or varicella vaccination. If the his-
tory is unclear, titers should be drawn and patients should 
be vaccinated if they lack adequate protection. Although 
a history of wild-type infection or vaccination is generally 
a good predictor of a good antibody level,26,33 obtaining 
titers would still be helpful because antibody levels may 
wane over time.32,33
In the difficult scenario in which a child is expected 
to start immunosuppressive therapy but needs to be vac-
cinated, there should be at least a 4-week interval between 
vaccination and onset of immunosuppressive therapy.31,32 
Therefore, the medical care provider should weigh the ben-
efits and risks. Factors contributing to the decision-making 
process include the child’s disease activity (because therapy 
should be withheld for at least 4 weeks), risk of vaccine-
associated adverse events, potential for exposure to wild-
type varicella, and possible complications of chickenpox 
while on immunosuppressive therapy if not immunized. 
If the medical care provider decides to immunize a child 
while receiving immunosuppressive therapy, consulting an 
infectious disease specialist would be helpful. 
If a child on immunosuppressive therapy is not 
immune to varicella and has significant exposure to active 
varicella, varicella zoster immune globulin (VariZIG, 
Cangene Corporation) or acyclovir should be given. 
Varicella zoster immune globulin should be administered 
as soon as possible and within 96 hours of exposure. If 
the exposure has exceeded 96 hours, or if varicella zos-
ter immune globulin is not available, some recommend 
giving acyclovir within 7 to 10 days of exposure.32 If an 
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immunocompromised child acquires wild-type varicella 
infection, intravenous acyclovir should be administered.32
A case series consisting of 6 children with IBD who 
were administered varicella vaccine while on treatment 
with either 6-MP or infliximab found that an immune 
response developed in 5 of the 6 children. All 6 children 
tolerated the vaccine without adverse events.60 Therefore, 
in the situation in which there is a high incidence of 
wild-type varicella, it is important to have a discussion 
with the patient’s family about weighing the benefits of 
protection from wild-type varicella against the risks of 
vaccine-associated adverse events.
A retrospective study conducted by Ansari and col-
leagues evaluated the vaccination history and varicella 
titers of 163 pediatric patients with IBD.61 The investiga-
tors found that two-thirds of patients had either a history 
of chickenpox or received at least 1 vaccine dose. At the 
diagnosis of IBD, 77% of patients had a documented 
positive titer, 11% had a negative titer, and the remaining 
12% did not have an antibody level available. Ten patients 
with a negative or unknown titer were immunized prior 
to starting immunosuppressive therapy. Postvaccination 
antibody levels were obtained in 8 of these 10 patients, 
and all 8 responded.
Household Contacts of Patients with 
Inflammatory Bowel Disease
It is important that household members of children with 
IBD who are receiving immunosuppressive therapy are up-
to-date with routine immunizations to minimize infections 
in patients. It is recommended that household contacts 
receive the necessary inactivated vaccinations, including the 
intramuscular influenza vaccine (not intranasal influenza 
vaccine, which is a live vaccine). Household members also 
can receive the MMR vaccine without being concerned 
of harm or viral spread to the patient.31,62 Household 
members can receive the varicella vaccine; however, if a 
vaccine-related rash develops in contacts, they should avoid 
close contact with the pediatric patient if the patient has 
no immunity to varicella. In this situation, varicella zoster 
immune globulin is not indicated because secondary infec-
tion from the vaccine is expected to be mild.31,63
Summary
Although advances in medicine have produced medica-
tions to help control IBD and improve quality of life, 
patients are at an increased risk for infection due to these 
medications. Therefore, it is important to minimize infec-
tions and their associated complications by simply vac-
cinating patients to avoid the morbidity and mortality of 
a vaccine-preventable infection. 
Unfortunately, the immunization rate is low in young 
patients with IBD, partly due to the lack of appropriate 
counseling and attention on the part of the gastroenterol-
ogist and also concern about vaccine-associated complica-
tions or low efficacy on the part of the gastroenterologist 
and patient. As gastroenterologists, we sometimes play 
the role of PCPs because patients have regular contact/
visits with us and turn to us first for medical advice even if 
the topic is not directly related to our field. Therefore, we 
have the potential to play a critical role in helping patients 
remain up-to-date with immunizations and should be 
more proactive in helping them stay healthy with this 
simple yet valuable tool.
Current guidelines recommend that patients with 
IBD follow the same routine immunization schedule as 
healthy children but should avoid live vaccines if receiving 
immunosuppressive therapy. Children can be given inac-
tivated vaccines regardless of immunosuppression status.30 
It is preferable for physicians to check the immunization 
status of their patients at the time of diagnosis and immu-
nize patients with any necessary vaccines prior to starting 
immunosuppressive therapy, especially in the case of live 
vaccines. Obtaining antibody levels (to hepatitis A virus, 
HBV, MMR, and varicella) may be helpful in cases in 
which the history of vaccination or wild-type infection is 
unclear or to confirm that titers are at an adequate level. 
However, vaccination does not necessarily translate into 
adequate immunization. The data in both adult and pedi-
atric IBD literature reveal that inactivated vaccines are 
generally safe and effective and do not exacerbate IBD. 
However, immunogenicity may be lower in patients on 
immunosuppressive therapy, especially TNF inhibitors. 
Despite this, having a suboptimal immunogenicity is still 
better than a complete lack of titers because having at least 
some immunogenicity offers a degree of protection. 
Future studies are much needed to evaluate the safety 
and immunogenicity of individual vaccines using different 
doses and schedules in patients with IBD receiving various 
therapies, especially immunosuppressive medications. It is 
also important to evaluate the sustainability of titers, as anti-
body levels may wane over time, leaving patients and medical 
care providers falsely assuming that patients are adequately 
protected when they are actually susceptible.
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